Rx Savings Solutions finds the cheaper prescription hiding in your benefits

The question at the pharmacy counter was brutally practical: which medicine could she do without? In a 2017 interview, Michael Rea recalled a customer taking eight medications who could no longer afford the bill. He researched her options and found a way to cut the cost by $250 a month. The prescriptions had become a household arithmetic problem. A pharmacist had found another answer.

That encounter supplies the premise of Rx Savings Solutions, usually shortened to RxSS. Useful options can exist without being obvious to the person paying. Someone must uncover them, explain them and help put them into practice. The company sells that work as software paired with pharmacy expertise.

The wrong person was doing the searching

Rea had worked at Walgreens, where patients repeatedly asked why their drugs cost more. His early venture aimed directly at consumers. By 2017, it had shifted toward employers and insurers, which could offer the service to employees and members. This was a consequential change in who bought the help and how people encountered it.

Consider the difference. A person already struggling with a prescription bill must first discover a consumer service, decide whether to trust it and learn how to use it. An employer or health plan can place the same assistance inside an existing benefit. The company gains a route to groups of eligible members, rather than having to win each household separately.

The early business was difficult. The Kansas City Business Journal reported in 2022 that Rea had come close to giving up about six years into building the company. The public record documents the distribution change; it does not warrant a neat story in which one meeting or one revelation solved everything. What followed was capital, software development and the slow business of persuading organizations to adopt a benefit.

In 2017, McCarthy Capital led an $18.4 million investment round. Rea told MedCity News that roughly 70 percent would support sales and marketing, with the rest going to software enhancements. Even a company founded on clinical insight had to budget for getting its product into people’s hands.

“Would we recommend this to our family?”The RxSS clinical committee’s test for a savings suggestion

A cheaper capsule, a different question

Prescription shopping sounds like a hunt for the lowest price on an identical item. RxSS also asks whether there is another clinically appropriate way to fill the need: a generic, a different dosage form or a therapeutic alternative. Its technology page gives the wonderfully unglamorous example of a tablet versus a capsule. A small difference on the shelf can become a meaningful line in a budget.

The comparison must account for the member’s benefit. A health plan’s formulary, coverage and negotiated prices affect whether a suggestion offers savings. An option that looks attractive in the abstract may lose its charm when the insurance rules arrive. RxSS uses claims and benefit information to make the search personal.

The expertise behind that search is clinical as well as technical. Its Pharmacy and Therapeutics Committee maintains the suggestions database, reviews new drugs and safety information, and evaluates prescriber acceptance and denial rates. The committee explicitly considers simplicity and convenience alongside cost. A confusing or awkward switch may be poor help, however elegant its spreadsheet.

This mixture also appears in the workforce. The company recruits engineers, designers, quality analysts, pharmacists and pharmacy technicians. Its careers page describes a casual, professional workplace with room for a balanced lifestyle. That is the employer’s account of its culture; the more concrete observation is that the product requires both people who understand medications and people who build software.

The last mile has a telephone

The portal lets members search medication prices and view savings opportunities. Personalized outreach can arrive by email, text, mail or phone. The engagement program draws on claims, plan design and previous engagement data to choose the message and channel. The opportunity goes looking for the member.

Then comes the part a comparison screen cannot finish. A prescription change may need a doctor’s approval. A transfer may need coordination with a pharmacy. RxSS’s support team helps make those contacts, follows up and tells the member when the new prescription is ready. The promise includes assistance with the chore attached to the cheaper option.

Here the buyer and the user have different jobs. An employer or health plan contracts for the SaaS and support service. A member decides whether to engage with a suggestion. RxSS sits between the organizational ambition to manage spending and the individual’s immediate wish to collect medicine without an unpleasant financial surprise.

Purdue puts participation beside the dollars

Purdue University introduced RxSS to its employee medical plan in January 2020. A published case study describes a plan covering 23,000 people. Within 90 days, 22 percent of members with pharmacy claims had engaged. By November 2022, the reported engagement rate reached 32 percent; 37 percent of those engaged had switched to lower-cost options.

These are vendor-published figures. The case study describes analysis by a healthcare data firm, including comparison of participants and nonparticipants with risk grouping. It reports an association between engagement and cost reduction. This is useful evidence about a particular program, with a different evidentiary weight from a randomized experiment.

The later account extends the story. In an April 2026 conference recap, RxSS reported that Purdue had accumulated more than $2 million in savings over several years, including $725,000 during 2025. Those newer numbers came from RxSS data. They belong to their own reporting period, rather than being silently added to the earlier total.

For a benefits buyer, this suggests a sensible line of inquiry: ask who participated, who changed prescriptions and which savings were realized. Registration is a beginning. A completed change provides another piece of evidence. The headline number becomes more useful when its route is visible.

The $600 million cheque, with conditions attached

McKesson announced its acquisition agreement in September 2022 and completed the purchase on November 1. Its SEC filing records $600 million in upfront cash and up to $275 million in contingent consideration tied to operational and financial performance through 2025. The widely quoted $875 million was the maximum deal value.

The acquisition placed RxSS inside McKesson’s Prescription Technology Solutions business. At announcement, McKesson said more than 17 million members had access to the service. The current clinical-committee page describes nearly 19 million. Access measures potential reach; it does not establish that everyone registered, switched or saved.

RxSS occupies a particular place in the pharmacy market: an added service working with the existing health plan and pharmacy benefit manager. Its 2019 Accolade relationship brought prescription savings into a broader benefits-advocacy offering. It is also listed in Personify Health’s partner marketplace. Those relationships offer further routes to members.

The useful thing to borrow

GoodRx and PBM member tools are among the other routes people use to compare prescription costs. RxSS’s technology page now describes GoodRx pricing inside its portal, alongside clinical guidance. The competitive boundary is porous: a price-shopping alternative can also supply an option within the service.

The member still needs the whole calculation. RxSS cautions that discount-card payments may not count toward a plan deductible, and that enabling its optional discount-card feature requires PBM consent. Specialty drugs may offer fewer therapeutic alternatives. A lower-cost option also has to suit the patient, and any required prescription change needs the prescriber’s agreement.

A reader can borrow a practical habit: compare benefit-specific options before the prescription is written, where possible, and ask for help with the steps a change requires. A product builder can borrow the underlying design principle: connect a specific opportunity to an achievable next action. RxSS began with a pharmacist doing research for one patient. Its business is an attempt to make that useful intervention repeatable.